Asset Details
Do you wish to reserve the book?
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
Do you wish to request the book?
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
2017
Overview
The JmjC histone demethylases (KDMs) are linked to tumour cell proliferation and are current cancer targets; however, very few highly selective inhibitors for these are available. Here we report cyclic peptide inhibitors of the KDM4A-C with selectivity over other KDMs/2OG oxygenases, including closely related KDM4D/E isoforms. Crystal structures and biochemical analyses of one of the inhibitors (CP2) with KDM4A reveals that CP2 binds differently to, but competes with, histone substrates in the active site. Substitution of the active site binding arginine of CP2 to
N
-ɛ-trimethyl-lysine or methylated arginine results in cyclic peptide substrates, indicating that KDM4s may act on non-histone substrates. Targeted modifications to CP2 based on crystallographic and mass spectrometry analyses results in variants with greater proteolytic robustness. Peptide dosing in cells manifests KDM4A target stabilization. Although further development is required to optimize cellular activity, the results reveal the feasibility of highly selective non-metal chelating, substrate-competitive inhibitors of the JmjC KDMs.
JmjC histone demethylases (KDMs) are cancer targets due to their links to cell proliferation, but selective inhibition remains a challenge. Here the authors identify potent inhibitors of KDM4A-C—via
in vitro
selection from a vast library of cyclic peptides—that show selectivity over other KDMs.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 82
/ 82/75
/ Enzyme Inhibitors - pharmacology
/ Genomics
/ Humanities and Social Sciences
/ Humans
/ Jumonji Domain-Containing Histone Demethylases - antagonists & inhibitors
/ Jumonji Domain-Containing Histone Demethylases - metabolism
/ Peptides
/ Peptides, Cyclic - pharmacology
/ Proteins
/ Science
